Skin disorder caused by infection
MONDO:0024294Skin diseases caused by bacteria, fungi, parasites, or viruses.
Also known as: disease, infectious skin, diseases, infectious skin, infectious skin disease, infectious skin diseases, skin disease, infectious
322 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New shingles vaccine trial aims for safer protection in adults 40+
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONThis early-stage trial tests a new shingles vaccine in 120 adults aged 40 and older. The main goal is to check safety and side effects at different doses, while also looking at how well the vaccine triggers an immune response. Participants receive either the vaccine or a placebo,…
Phase: PHASE1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:05 UTC
-
New shingles vaccine Z-1018 takes on shingrix in Head-to-Head trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new shingles vaccine called Z-1018 in about 764 healthy adults aged 50 and older. It compares Z-1018 to the current vaccine, Shingrix, to see if it is safe and triggers a strong immune response. The trial is in early phases (1 and 2), so the main focus is on sa…
Phase: PHASE1, PHASE2 • Sponsor: Dynavax Technologies Corporation • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
MRNA vaccine takes on shingles: could it beat shingrix?
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing a new mRNA vaccine called ABO1108 to prevent shingles in adults aged 40 and above. Around 180 healthy volunteers will receive two shots of either the new vaccine at different doses, a placebo, or the existing Shingrix vaccine. The main goal is to…
Phase: PHASE1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:32 UTC
-
New mRNA shingles vaccine shows promise in Mid-Stage trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new mRNA vaccine called ABO1108 to see if it can prevent shingles in adults aged 40 and above. About 300 healthy volunteers will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the immune response and check for sa…
Phase: PHASE2 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:31 UTC
-
Can an EV71 vaccine protect older kids too?
⭐️ VACCINE ⭐️ OngoingThis study tests an inactivated EV71 vaccine (Envacgen®) in healthy children aged 6 to under 10 years and compares their immune response and safety to children aged 2 to under 6 years. Around 378 children will receive two shots 57 days apart. The goal is to see if the vaccine wor…
Phase: PHASE3 • Sponsor: Medigen Vaccine Biologics Corp. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
New shingles vaccine shows promise in Head-to-Head trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new shingles vaccine called JCXH-105 in healthy adults aged 50 and older. It compares the new vaccine to the current standard, Shingrix, to see if it is safe and triggers a strong immune response. About 467 participants will receive either JCXH-105 or Shingrix,…
Phase: PHASE2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New shingles vaccine trial aims to protect millions over 40
⭐️ VACCINE ⭐️ OngoingThis study tests a new shingles vaccine in 960 healthy adults aged 40 and older. The goal is to see if it is safe and triggers a strong immune response. Researchers will monitor side effects and measure antibody levels over time. This is an early-stage trial to help develop a bet…
Phase: PHASE1, PHASE2 • Sponsor: Ab&B Bio-tech Co., Ltd.JS • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:01 UTC
-
Could this new vaccine stop shingles for years?
⭐️ VACCINE ⭐️ OngoingThis Phase 3 trial is testing a new shingles vaccine in 12,000 adults aged 40 and older. The goal is to see if the vaccine can prevent shingles for up to 3 years after the two-dose series. Participants previously received the vaccine or a placebo, and researchers are tracking who…
Phase: PHASE3 • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:00 UTC
-
New vaccine could stop recurring yeast infections in their tracks
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine called Candi5V in 251 women who get frequent yeast infections (at least 3 per year). The vaccine is designed to train the body's immune system to fight Candida fungus. Researchers will check if it's safe and if it reduces future infections.
Phase: PHASE1, PHASE2 • Sponsor: LimmaTech Biologics AG • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:10 UTC
-
New shingles vaccine candidate enters Mid-Stage trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new shingles vaccine called LYB004 in 840 adults aged 40 and older in China. Participants receive one of four different doses of the vaccine or a placebo. The goal is to see how well the vaccine triggers an immune response and whether it is safe.
Phase: PHASE2 • Sponsor: Guangzhou Patronus Biotech Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:07 UTC
-
New shingles vaccine CRV-101 takes on shingrix in Head-to-Head trial
⭐️ VACCINE ⭐️ OngoingThis phase 2 study tests a new shingles vaccine called CRV-101 (amezosvatein) against the current standard, Shingrix, in about 1,500 adults aged 50 and older. The goal is to see if CRV-101 is safer and triggers a strong immune response. Participants receive two shots and are moni…
Phase: PHASE2 • Sponsor: Curevo Inc • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:53 UTC
-
Wart war: two injections face off in plantar wart study
Disease control OngoingThis study tests two injected medications, bleomycin and pingyangmycin, for treating plantar warts. Each of the 200 adult participants will receive both drugs on different warts to compare which works better. The main goal is complete clearing of the warts, with follow-up for 36 …
Phase: PHASE4 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New antibody drug aims to calm painful skin condition
Disease control OngoingThis Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…
Phase: PHASE2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for HS sufferers: Long-Term drug trial expands
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 adults and teens who completed an earlier sonelokimab study will receive the drug for an e…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Viruses vs. superbugs: new hope for skin infections?
Disease control ENROLLING_BY_INVITATIONThis study tests a mixture of viruses called phages, which naturally kill bacteria, for treating skin infections that don't respond to antibiotics. Researchers will enroll 150 adults with infected wounds and compare the phage treatment to a placebo or standard care. The goal is t…
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
At-Home light therapy could zap nail fungus
Disease control OngoingThis study tests a new home-use LED light device to treat nail fungus (onychomycosis). Researchers want to find the best light dose and how often to use it. Fifty adults with nail fungus will use the device at home and be monitored for improvement.
Phase: NA • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug trial aims to help teens with painful skin condition
Disease control OngoingThis study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers wi…
Phase: PHASE3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could shorter antibiotic courses be better for hospitalized kids?
Disease control ENROLLING_BY_INVITATIONThis study aims to find out if 5 days of antibiotics works as well as 10 days for children hospitalized with pneumonia, skin infections, or urinary tract infections. About 1,200 children will be randomly assigned to either a 5-day or 10-day course, with some receiving a placebo a…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells plus chickenpox vaccine take on childhood cancers
Disease control OngoingThis early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Shingles vaccine trial for transplant recipients: a safety check
Disease control ENROLLING_BY_INVITATIONThis study looks at whether the shingles vaccine is safe and works well in young adults (19 and older) who have had a solid organ transplant. About 80 participants will get two doses of the vaccine and be monitored for side effects and immune response. The goal is to help protect…
Phase: PHASE4 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Hospital at home: new study tests home care for infections
Disease control OngoingThis study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…
Phase: NA • Sponsor: Copenhagen University Hospital at Herlev • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New stitch technique aims to stop rare lung complication
Disease control ENROLLING_BY_INVITATIONThis study tests if an extra stitch between the ribs during lung surgery can prevent a rare complication called lung hernia, where lung tissue bulges through the chest wall. About 104 adults having lung surgery will be split into two groups: one gets the extra stitch, the other g…
Phase: NA • Sponsor: Mingjian Ge • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New topical drug could tackle stubborn toenail fungus
Disease control OngoingThis study tests a topical solution called Trichostatin A for mild-to-severe toenail fungus (onychomycosis). About 50 adults with a confirmed fungal infection will apply the drug daily for 4 weeks. Researchers will check safety and whether the fungus clears up using lab tests.
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a stronger antibiotic dose keep cellulitis patients out of hospital?
Disease control ENROLLING_BY_INVITATIONThis study tests whether a higher dose of the oral antibiotic cephalexin can better treat cellulitis, a common skin infection, in adults visiting the emergency room. About 446 participants will receive either a high or standard dose to see if it reduces the need for changing anti…
Phase: PHASE4 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can light zap eyelid mites? new trial investigates
Disease control ENROLLING_BY_INVITATIONThis study tests two types of light therapy—low-level light and intense pulse light—to kill Demodex mites that cause eyelid inflammation (blepharitis). 88 adults with confirmed mite infections will receive one of four treatments: sham, blue light alone, IPL alone, or both. All wi…
Phase: NA • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 26, 2026 16:09 UTC
-
Shingles shot put to the test in older HIV patients
Disease control OngoingThis study looks at how well the Shingrix vaccine protects against shingles in people over 50 living with HIV, compared to healthy adults of the same age and gender. About 225 participants will receive two doses of the vaccine and be monitored for one year. The goal is to see if …
Phase: PHASE4 • Sponsor: Calmy Alexandra • Aim: Disease control
Last updated Jun 26, 2026 13:35 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Can adding a simple skin snip boost cellulite treatment?
Symptom relief OngoingThis study tests whether freezing fat cells (cryolipolysis) works better for cellulite when combined with a minor procedure that cuts the fibrous bands pulling down the skin (subcision). Fifteen healthy women with moderate to severe cellulite on both outer thighs will receive one…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Wrestlers try Beta-Alanine to boost performance and fight fatigue
Symptom relief OngoingThis study looks at whether taking beta-alanine, a common supplement, can help wrestlers perform better and feel less muscle fatigue during two days of simulated matches. Sixteen healthy wrestlers aged 12 to 25 will take the supplement and then do wrestling drills to measure thei…
Phase: NA • Sponsor: China Medical University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New thrush treatment shows promise in early trial
Symptom relief OngoingThis study tests a product called pHyph for treating thrush (a vaginal yeast infection) in adult women. The goal is to see if pHyph reduces symptoms like itching, burning, and irritation. 48 women will either use pHyph daily for 6 days or receive no treatment, and researchers wil…
Phase: NA • Sponsor: Gedea Biotech AB • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Could a different anesthesia method help diabetics during surgery?
Symptom relief OngoingThis study compares total intravenous anesthesia (TIVA) to balanced anesthesia (using inhaled gas) in 60 diabetic patients undergoing video-assisted chest surgery. The goal is to see which method better controls blood sugar and reduces stress during surgery. Researchers will also…
Phase: PHASE4 • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Shingles pain breakthrough? injections may beat standard drugs
Symptom relief OngoingThis study tests whether injecting a mix of lidocaine and steroids into tender points can better relieve shingles pain compared to standard painkillers alone. The trial involves 136 adults with severe shingles pain for less than 90 days. Researchers will track pain levels for up …
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 26, 2026 13:48 UTC
-
Mystery infections in healthy people: scientists investigate
Knowledge-focused OngoingThis study looks at HIV-negative people who get opportunistic infections—illnesses that usually only affect those with weak immune systems. Researchers want to find out if these patients have unusual antibodies that block a key immune signal. Up to 224 adults in Thailand and Taiw…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Do vaccines still work during lymphoma treatment? new study aims to find out
Knowledge-focused OngoingThis study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Shingrix vaccine study probes skin immunity in young and old
Knowledge-focused OngoingThis study looks at how the Shingrix vaccine, which protects against shingles, affects immune cells in the skin and blood. Researchers will give the vaccine to 50 healthy adults in two age groups: 30-40 years old and 70 years or older. They will measure specific antibodies and T-…
Phase: PHASE4 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists dig into the vaginal microbiome to unlock secrets of recurrent yeast infections
Knowledge-focused OngoingThis study looks at 120 Canadian women to understand why some get repeated yeast infections while others don't. Researchers will compare the vaginal yeast and bacteria of women with their first infection, those with recurrent infections, and those with yeast but no symptoms. Part…
Phase: EARLY_PHASE1 • Sponsor: University of Manitoba • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to find safe scabies treatment for toddlers
Knowledge-focused OngoingThis study looks at how well a single dose of ivermectin works in children under 5 with scabies. Researchers want to make sure the dose is safe and effective for this age group. About 120 children in Laos will take part, and the study will measure drug levels in the blood.
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Could a Baby-Friendly ivermectin formula beat scabies?
Knowledge-focused TerminatedThis trial compares a new ivermectin powder mixed with infant formula to the standard tablet in 52 healthy adults. The goal is to see if the new formulation is absorbed similarly, tastes better, and causes no new side effects. Results will guide future use in children with scabie…
Phase: PHASE1 • Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
AI predicts hospital stays, but study never started
Knowledge-focused TerminatedThis study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
AI vs. skin doctors: who diagnoses better?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New hospital program aims to cut unnecessary antibiotics for kids
Knowledge-focused OngoingThis study tests a 'discharge stewardship bundle' to help doctors prescribe the right antibiotics for the right duration when children leave the hospital. Over 1,100 children with pneumonia, urinary tract infections, or skin infections will be followed. Doctors receive feedback r…
Phase: NA • Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Shingles vaccine safety in pregnancy under review for immunocompromised women
Knowledge-focused OngoingThis study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Coffee warning for nail fungus patients?
Knowledge-focused ENROLLING_BY_INVITATIONThis study checks if drinking caffeine changes blood pressure or heart rate in people taking the antifungal medication terbinafine for nail fungus. Researchers will monitor 52 adults before and after they start the drug. The goal is to understand possible side effects, not to tes…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Beach danger? new study tracks illness from toxic algae
Knowledge-focused OngoingThis study follows 2,500 people who visit freshwater beaches in Ontario, Manitoba, and Nova Scotia to see if contact with water containing blue-green algae (cyanobacteria) leads to stomach bugs, respiratory issues, or skin/eye infections. Researchers will also track illness in pe…
Sponsor: Toronto Metropolitan University • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:54 UTC